Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 0 results

Early research (Phase 1)UnknownNCT05315830
What this trial is testing

HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric

Who this might be right for
Adenocarcinoma - GEJAdenocarcinoma of the Stomach
The First Affiliated Hospital of Bengbu Medical University 10
Testing effectiveness (Phase 2)Study completedNCT04014075
What this trial is testing

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Who this might be right for
Adenocarcinoma Gastric Stage IV With MetastasesAdenocarcinoma - GEJ
Daiichi Sankyo 79
Large-scale testing (Phase 3)Looking for participantsNCT06901531
What this trial is testing

Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Large-scale testing (Phase 3)Looking for participantsNCT06123494
What this trial is testing

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

Who this might be right for
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd. 360
Not applicableActive Not RecruitingNCT05993234
What this trial is testing

Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

Who this might be right for
HER2-positive Advanced Gastric CancerHER2-positive Gastroesophageal Junction Adenocarcinoma
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company 257
Large-scale testing (Phase 3)Active Not RecruitingNCT06238843
What this trial is testing

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)

Who this might be right for
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd. 464
Not applicableNot Yet RecruitingNCT07780968
What this trial is testing

Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA

Who this might be right for
Esophageal CancerGastroEsophageal CancerGastroesophageal-junction Cancer+2 more
Jazz Pharmaceuticals 300
Not applicableStudy completedNCT01220934
What this trial is testing

An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 443
Testing effectiveness (Phase 2)Study completedNCT04309578
What this trial is testing

Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC

Who this might be right for
Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma
Asan Medical Center 28
Testing effectiveness (Phase 2)Looking for participantsNCT07334431
What this trial is testing

Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaGastric (Stomach) CancerGEJ Adenocarcinoma+3 more
Henan Cancer Hospital 45
Not applicableAvailableNCT06048081
What this trial is testing

Early Access Program for Zolbetuximab

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma CancerLocally Advanced Unresectable Gastric Adenocarcinoma CancerMetastatic Gastric Adenocarcinoma Cancer+1 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07716111
What this trial is testing

Neoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University 24
Testing effectiveness (Phase 2)Study completedNCT01748773
What this trial is testing

The Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Hoffmann-La Roche 34
Large-scale testing (Phase 3)Study completedNCT04499924
What this trial is testing

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaEsophageal Adenocarcinoma
Seagen Inc. 17
Testing effectiveness (Phase 2)Looking for participantsNCT06730373
What this trial is testing

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Who this might be right for
HER2-positive Gastric CancerMetastatic Gastric CancerUnresectable Gastric Carcinoma
Qilu Hospital of Shandong University 110
Large-scale testing (Phase 3)UnknownNCT00450203
What this trial is testing

Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer

Who this might be right for
Oesophagogastric Cancer
Professor David Cunningham 1,103
Large-scale testing (Phase 3)Ended earlyNCT01450696
What this trial is testing

Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 296
Large-scale testing (Phase 3)Looking for participantsNCT05427383
What this trial is testing

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Who this might be right for
Stomach Cancer
Shanghai JMT-Bio Inc. 286
Early research (Phase 1)Study completedNCT03368196
What this trial is testing

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Who this might be right for
Adenocarcinoma, GastricNeoplasm, Breast
Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company 12
500